The effect of ceftriaxone on tobramycin-induced nephrotoxicity was investigated. Female Sprague-Dawley rats were treated during 4 and 10 days with saline (NaCl, 0.9%), ceftriaxone at a dose of 100 mg/kg of body weight/12 h subcutaneously, tobramycin at doses of 40 and 60 mg/kg/12 h intraperitoneally, or the combination ceftriaxone-tobramycin. Creatinine levels in serum were significantly higher in animals treated with tobramycin alone given at 60 mg/kg/12 h during 10 days, compared with control animals (P < 0.01) or animals receiving the combination tobramycin-ceftriaxone (P < 0.01). After 10 days of treatment, ceftriaxone did not accumulate in renal tissue but did reduce the renal intracortical accumulation of tobramycin (P < 0.05). Tobramycin given alone at either 40 or 60 mg/kg/12 h induced a significant inhibition of sphingomyelinase activity compared with control animals (P < 0.05). However, this enzyme activity was significantly less inhibited when tobramycin was injected in combination with ceftriaxone (P < 0.05). Ceftriaxone alone had no effect on the activity of this enzyme. The [3H]thymidine incorporation into the DNA of renal cortex was also significantly lower in animals treated with tobramycin-ceftriaxone compared with animals receiving tobramycin alone (P < 0.05). The 24-h urinary excretion of 0-galactosidase was significantly reduced in animals treated with the combination tobramycin-ceftriaxone compared with the administration of tobramycin alone at 40 and 60 mg/kg/12 h after 5 and 10 days (P < 0.05). Histologically, ceftriaxone induced very few cellular alterations and reduced considerably the presence of typical signs of tobramycin nephrotoxicity. This investigation demonstrates that ceftriaxone protects animals against tobramycin-induced nephrotoxicity.
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Ceftriaxone is a broad-spectrum cephalosporin. As with all other P-lactams, the antibacterial activity of ceftriaxone is due to inhibition of mucopeptide synthesis in the cell wall (2, 28, 32) . Ceftriaxone possesses a broad spectrum of antimicrobial activity including aerobic gram-positive and gram-negative bacteria and also a few anaerobic bacteria (2, 36, 41) . The drug is widely used in the treatment of infections caused by microorganisms resistant to conventional therapy or as an alternative to antibiotics with a low therapeutic index. In combination with aminoglycosides, ceftriaxone has been shown to be additive or synergistic against several gram-negative pathogens (1, 45) . The efficacy and safety of the combination ceftriaxone-aminoglycosides have already been evaluated in experimental models of infections (18, 20) as well as in patients (9, 25, 29, 34, 43) .
Aminoglycosides are eliminated essentially by glomerular filtration and partially reabsorbed by proximal tubular cells by a mechanism of pinocytosis into small vesicles that fuse with lysosomes where they accumulate (3, 24, 42) . They induce a lysosomal phospholipidosis characterized by the inhibition of sphingomyelinase and phospholipase Al activity and by phospholipid accumulation into lysosomes (30) . This phospholipidosis is accompanied by cellular necrosis and postnecrotic cell regeneration (23, 31, 33) .
Different compounds or drugs used concomitantly with aminoglycosides may either increase (vancomycin, cisplatinum, and hydrocortisone [6, 7, 16, 38, 48] ) or decrease (ticarcillin, carbenicillin, cephalothin, latamoxef, daptomycin, and poly-L-aspartic acid [4-6, 10, 14, 17, 22, 27, 28 , 47]) their toxicity. There is no direct correlation between the toxicity of aminoglycosides, whether used alone or in combination, and their renal concentrations. In fact, in combination with cisplatinum, daptomycin, poly-L-aspartic acid, and ticarcillin, renal aminoglycoside levels increased (4, 5, 16, 17, 22, 47) , while they decreased with concomitant cephalothin, latamoxef, and vancomycin (14, 21, 27, 48) . Some studies even report no influence of daptomycin, vancomycin, cephalothin, and carbenicillin on aminoglycoside cortical accumulation (6, 10, 38) .
To our knowledge, there are no data on the influence of ceftriaxone on aminoglycoside-induced nephrotoxicity. Since ceftriaxone is often combined with an aminoglycoside and this combination was shown to be very effective as the first-line antibiotic combination in the treatment of several severe infections including those observed in febrile neutropenic patients (9, 29, 34) (35) .
Histology. At the time of sacrifice, a portion of the renal Microscopic renal lesions were scored on plastic sections at a magnification of x 400. Each slide was coded so that identification of the groups was not possible for the observer (G.T.). Slices came from three different pieces of renal cortex for each rat, and four rats per group were used. The following lesions in the renal cortex were scored: isolated cell necrosis, proximal tubule with large lysosomes, abnormal proximal tubules (proximal tubule with more than 50% of necrotic cells), tubular desquamation (proximal tubule with 100% of necrotic cells), metachromatic materials in the tubular lumina, and the number of interstitial cells (no specification of cell type was made). The total number of proximal tubules was also measured on each slice. The number of isolated necrotic cells, the number of proximal tubules with large lysosomes, the number of abnormal proximal tubules, the number of desquamated tubules, and the number of proximal tubules with metachromatic materials in the tubular lumina were recorded as percentages of the total number of proximal tubules on each respective slice and assigned a score as follows: 0 to 9%, 1; 10 to 19%, 2; 20 to 29%, 3; etc. A score for the interstitial cells was obtained by dividing the total number of interstitial cells by the total number of proximal tubules on each respective slice. The lesion scores were summed to produce a single toxicity score for each animal.
Statistics. Statistical analysis of the difference between groups was performed by analysis of variance using a leastsquares method. For a P value under 0.05, a group comparison was done by using the Fisher protected less significant difference test. A P value of less than 0.05 was considered significant.
RESULTS
Concentrations of ceftriaxone in serum, urine, and renal cortex measured from 1 to 24 h after a single subcutaneous injection of 100 mg/kg are shown in Table 1 Fig. 1 . After 10 days of treatment, ceftriaxone significantly reduced the intracortical accumulation of tobramycin administered at 40 and 60 mg/kg/12 h (P < 0.05). After 4 days, the same effect was observed when ceftriaxone was given in combination with tobramycin at 40 mg/kg/12 h (P < 0.05). Figure 2 shows creatinine levels in sera of animals of all groups after 10 days of treatment. There was no significant difference between animals treated during 4 days (data not shown). A significant rise in creatinine levels in sera of animals treated with tobramycin alone at a dose of 60 mg/kg/12 h compared with all other groups was observed (P < 0.01). However, serum creatinine levels were no different from control groups when tobramycin was given in combination with ceftriaxone, suggesting, once again, that the combination between these two drugs is less toxic than tobramycin given alone. Figure 3A shows the influence of ceftriaxone on tobramycininduced inhibition of sphingomyelinase activity after 10 days of treatment. At day 10, tobramycin given at 40 and 60 mg/kg/12 h induced a significant inhibition of sphingomyelinase activity compared with the saline-treated group (P < 0.01). There was no significant difference between the group receiving tobramycin at a dose of 40 mg/kg/12 h and the group receiving 60 mg/kg/12 h. However, sphingomyelinase activity was significantly less inhibited when tobramycin (40 and 60 mg/kg/12 h) was given in combination with ceftriaxone compared with rats treated with tobramycin alone (P < 0.05 to 0.01). Ceftriaxone alone induced a small inhibition of the enzyme activity, which, however, was not significant. After 4 days of treatment, no significant inhibition of the enzyme activity was observed in any groups (data not shown). [3H]thymidine incorporation, respectively, compared with control groups (P < 0.01). By contrast, when ceftriaxone was used in combination with tobramycin, the [3H]thymidine incorporation was similar to that for control animals, suggesting that ceftriaxone protects kidney cells against tobramycin toxicity. There was no significant difference between groups after 4 days of treatment. Table 2 shows the 24-h urinary excretion of ,-galactosidase for each treated group on days 0, 5, and 10 following the beginning of treatment. No significant difference in the excretion of this enzyme was observed between any groups on day 0. By contrast, 3-galactosidase excretion was significantly higher on days 5 and 10 in the urine of animals treated with tobramycin alone at a dose of 60 mg/kg/12 h compared with animals given saline (P < 0.05). This increase in the urinary excretion of ,B-galactosidase was significantly smaller when ceftriaxone was given in combination with tobramycin (60 mg/kg/12 h). In fact, the urinary excretion of ,B-galactosidase showed no significant difference between control animals and animals treated with the combination ceftriaxone-tobramycin (60 mg/kg/12 h).
Optic and electron microscopy showed typical signs of aminoglycoside nephrotoxicity in the renal cortices of animals treated with tobramycin alone given at either 40 or 60 mg/kg/12 h. Large lysosomes containing myeloid bodies were present in renal cortices of rats treated with tobramycin at both doses. More severe lesions were observed when tobramycin was given at the highest dose. Ceftriaxone given alone had no significant effect on kidney ultrastructure. By contrast, signs of aminoglycoside nephrotoxicity were significantly less important when ceftriaxone was administered concomitantly with tobramycin.
The mean score for each renal lesion and the mean histopathologic nephrotoxicity score in the renal cortex for each group treated during 10 days are shown in Table 3 served in rats treated with tobramycin at 60 mg/kg/12 h. By contrast, a lower score was measured in animals treated with the combination ceftriaxone-tobramycin (60 mg/kg/12 h) (P < 0.05). A similar effect was not observed when tobramycin was used at 40 mg/kg/12 h. The presence of tubular desquamation in the proximal tubule, which is a sign of acute tubular necrosis, was observed only in animals injected with tobramycin alone at 60 mg/kg/12 h. When ceftriaxone was administered with the same dose of tobramycin, no sign of tubular desquamation was observed (P < 0.05). Metachromatic material, which was composed of cellular debris and myeloid bodies in the lumina of proximal tubules, was observed only in tobramycin-treated animals. However, the frequency of the presence of metachromatic materials was significantly lower when ceftriaxone was added to tobramycin compared with animals given tobramycin alone (P < 0.05). No significant increase in the peritubular cell infiltration was observed in any group. The highest total mean nephrotoxicity scores were measured in animals treated with tobramycin administered at 40 and 60 mg/kg/12 h (P < 0.01).
By contrast, when ceftriaxone was given concomitantly with tobramycin at either 40 and 60 mg/kg/12 h, these scores were significantly lower (P < 0.05).
DISCUSSION
The present investigation demonstrates that ceftriaxone protects proximal tubular cells against tobramycin-induced nephrotoxicity. In fact, tobramycin cortical levels were significantly lower; the creatinine levels in serum were identical to those of saline-treated animals; the inhibition of sphingomyelinase activity was significantly less severe; and the cellular regeneration, the urinary excretion of ,-galactosidase, and the histopathologic lesions were significantly less affected in animals treated with the combination ceftriaxone-tobramycin compared with animals given tobramycin alone. Dellinger et al. (14) suggested that the protective effect of cephalothin was related to the presence of nonreabsorbable anion in the urine. Furuhama and Onodera (21) reported that the reduction of aminoglycoside nephrotoxicity by cephem antibiotics is due to their intrinsic nephrotoxic potential rather than the concentration of aminoglycoside in the kidney. Other investigators speculated that an interaction between tobramycin and ticarcillin which modifies tobramycin and lowers its toxic potential occurs in the renal proximal tubular cell (17) . More recently, Ohnishi et al. (39) concluded that the obligatory salt supplementation with ticarcillin is sufficient to induce the protective effect without having to infer a direct chemical interaction of the penicillin with the aminoglycoside. A dietary calcium loading was also shown to delay and attenuate gentamicin-mediated renal dysfunction and structural damage (8) .
Fosfomycin was also shown to decrease aminoglycoside nephrotoxicity. Increases in polyuria, enzymuria, blood urea nitrogen, and creatinine levels in serum induced by the administration of dibekacin were less severe when fosfomycin was given concomitantly (26) . Neuman (37) showed an improvement in the alanine-aminopeptidase excretion in urine when fosfomycin was injected in combination with amikacin. Furthermore, Palmieri et al. (40) demonstrated a decrease in nephrotoxicity and an increase in the antibacterial activity when fosfomycin was given in combination with gentamicin in patients.
Several mechanisms may be proposed for the observed protective effect of ceftriaxone on renal cells. While there is not necessarily a good correlation between the intracortical levels of aminoglycosides and renal toxicity, in our study we cannot eliminate the possibility that the marked reduction in the intrarenal accumulation of aminoglycoside in the presence of ceftriaxone might have protected renal cells against tobramycin toxicity. We and others have demonstrated that other protective agents such as daptomycin and poly-iL-aspartic acid protected proximal tubular cells against tobramycin and gentamicin nephrotoxicity, respectively, without reducing the uptake of the aminoglycosides (4) (5) (6) 22) . The mechanisms of protection for different antimicrobial agents are most likely different.
The mechanism by which tobramycin uptake by the renal tubule is disturbed is obscure, but on the basis of previous observations with other P-lactams, we cannot eliminate the possibility that ceftriaxone would have bound to tobramycin, thus disturbing its reabsorption in the proximal tubules. In fact, it has been shown that preincubation of aminoglycosides with penicillin antibiotics resulted in the formation of complexes (13, 15) . This would be consistent with the work of English et al. (17) , who reported that a 24-h preincubation of ticarcillin and tobramycin resulted in a more important decrease in nephrotoxicity than when ticarcillin and tobramycin were injected in combination without preincubation, resulting in lower levels of tobramycin in renal cells. By preventing binding of the aminoglycosides to renal membranes, thus diminishing reabsorption, ceftriaxone could protect the renal tubules against aminoglycoside toxicity (46) . Sodium salt loading is known to be of major importance in the prevention of nephrotoxicity induced by agents such as amphotericin B and glycerol (11, 44) . Ticarcillin and its obligatory sodium load were shown to reduce amphotericin B nephrotoxicity (12) . Ceftriaxone, like ticarcillin, requires an obligatory salt loading that represents less than half of the salt loading of ticarcillin. However, this may be sufficient to confer the protection against tobramycin-induced nephrotoxicity observed in this study. The mechanisms by which ceftriaxone protects against tobramycin-induced nephrotoxicity remains unclear, and further investigations are needed to better understand the mechanism and extent of this protective effect.
Aminoglycosides are frequently used in combination with ceftriaxone or other broad-spectrum cephalosporins for the treatment of patients with major infections. These patients are specially prone to renal damage caused by aminoglycosides. The potential protective effect of ceftriaxone against aminoglycoside toxicity obtained in the present study might add to the benefit of an additive or synergistic combination of antibiotics in very sick patients. Further 
